Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.

@article{Yang2010TargetedTA,
  title={Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.},
  author={Chih-Hsun Yang and Cheng-Keng Chuang and J Hsieh and John Wen-Cheng Chang},
  journal={Expert opinion on drug safety},
  year={2010},
  volume={9 3},
  pages={459-70}
}
IMPORTANCE OF THE FIELD Targeted therapy has significantly prolonged the survival of patients with advanced renal cell carcinoma (RCC). As first-line treatment, sunitinib, temsirolimus and bevacizumab plus IFN-alpha are demonstrated to prolong progression-free survival and/or overall survival. As second-line treatment, sorafenib was active mainly for patients in whom cytokine therapy failed. Recently, second-line treatment with everolimus has been shown to benefit patients progressing through… CONTINUE READING